Loading...

Home
ETF
ARVN

ARVN

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press

Markets

Market Analysis
Crypto
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

AI Strategies

AI Stock Picker
Swing Trading
SwingMax Portfolio
Quant AI Alpha Pick
CoinSwing
Daytrading Center
Crypto Radar
Patterns Detection

Resources

Blog
Tutorial
Help Center
Affiliate Program

Products

Chat With Tia
AI Screener
Backtest Playground
Featured Screeners
AI Earnings Calendar
Thematic Investing
Whales Auto Tracker

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

Explore AI Stock Picker
Master Swing Trading
Follow SwingMax Portfolio
Discover QuantAI Alpha Pick
Follow Whales Auto Tracker
Navigate Daytrading Center
Learn Patterns Detection
Meet Financial AI Agent
Maximize AI Screener
Why Backtesting Playground
Forecast AI Earnings Prediction
Setup Stock Monitor
Deep Dive into Tech Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

ARVN News

Arvinas Appoints New CEO Randy Teel Amid 11% Stock Drop

3d agostocktwits

Arvinas Appoints New CEO and Board Chair

3d agoseekingalpha

Analysis of Rapid Growth in the PROTAC Market

5d agoNewsfilter

Arvinas Initiates ARV-393 and Glofitamab Combination Trial for DLBCL Expected in 2026

Dec 06 2025Globenewswire

Arvinas Initiates ARV-393 and Glofitamab Combination Trial for DLBCL, Expected in 2026

Dec 06 2025Newsfilter

Arvinas to Participate in Piper Sandler Healthcare Conference on December 4

Nov 26 2025Globenewswire

Arvinas Unveils Preclinical Findings for ARV-806 Showcasing Strong and Unique Efficacy in KRAS G12D-Mutated Cancer Models at the 2025 AACR-NCI-EORTC Conference on Molecular Targets and Cancer Treatments

Oct 24 2025Newsfilter

Patient-Reported Outcomes from the VERITAC-2 Trial Indicate Clinical Benefits of Vepdegestrant for Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer After Endocrine Therapy

Oct 20 2025Newsfilter

Looking Ahead: 7 Analyst Predictions for Arvinas

Oct 15 2025Benzinga

Arvinas to Showcase Findings from the Vepdegestrant Clinical Development Program at the 2025 ESMO Congress

Oct 13 2025Newsfilter

Arvinas to Showcase Clinical Findings for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress on Parkinson's Disease and Movement Disorders®

Oct 01 2025Newsfilter

Arvinas Plans Job Reductions, Out-Licenses Vepdegestrant, and Initiates $100 Million Stock Buyback Program

Sep 18 2025NASDAQ.COM

Arvinas unveils $100 million stock buyback initiative

Sep 18 2025SeekingAlpha

Arvinas and Pfizer to License Out Commercialization Rights for Cancer Drug Vepdegestrant

Sep 17 2025SeekingAlpha

Daily Upgrade Report for Validea Kenneth Fisher Strategy - September 17, 2025

Sep 17 2025NASDAQ.COM

Cascade Prodrug Inc. Names Industry Experts Manuel (Manny) Litchman and Andres Gutierrez to Its Board of Directors

Aug 28 2025Yahoo Finance